Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937296 | 0.91 | PANK3 (0.48) | PANK3LMNASMN1; SMN2ALPLNAMPT | |
| SCHEMBL937430 | 0.82 | NAAA (0.50) | CNR1HPGD | |
| SCHEMBL20460443 | 0.82 | HPGD (0.49) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL938839 | 0.82 | ALPL (0.46) | JUNNFKB1NFKB2RELASMN1; SMN2 | |
| SCHEMBL937478 | 0.81 | NAAA (0.52) | LMNASMN1; SMN2CNR1HPGD | |
| SCHEMBL938874 | 0.81 | NAAA (0.52) | LMNASMN1; SMN2CNR1HPGD | |
| SCHEMBL18896207 | 0.81 | NAAA (0.52) | LMNASMN1; SMN2CNR1HPGD | |
| SCHEMBL8310937 | 0.80 | NPC1 (0.47) | JUNNFKB1NFKB2RELALMNA | |
| SCHEMBL8310344 | 0.80 | JUN (0.48) | JUNNFKB1NFKB2RELASMN1; SMN2 | |
| SCHEMBL938256 | 0.78 | JUN (0.42) | PANK3JUNNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | disclosed |
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| EP-2316827-A1 | Piperazine derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | PRXL2A, CUTA, MC1R | PANK3 2671/4885JUN 4366/4885NFKB1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.